

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Anatara Lifesciences Limited</b>
<b>ABN</b>	<b>41 145 239 872</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	David Brookes
<b>Date of last notice</b>	13 December 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect – Tarandi 1996 Pty Ltd (new trustee, formerly David & Elisabeth Brookes) atf Dr DL Brookes Personal Superfund & David & Elisabeth Brookes atf Dahlbrook Family Trust
<b>Date of change</b>	Ordinary Shares: 9 July 2024 Options: 9 July 2024

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<p>Direct:  Ordinary Shares: 1,240,000 Ordinary Shares  Options: 900,000 at \$0.225 ea; vesting 450,000 16 November 2022 &amp; 450,000 16 November 2023 expire 14 November 2025; and 175,000 Options exercisable at \$0.07 ea expiring 11 December 2025</p> <p>Indirect – Tarandi 1996 Pty Ltd atf Dr DL Brookes Personal Superfund 1,740,002 Ordinary Shares and 396,429 Options exercisable at \$0.07 ea expiring 11 December 2025  David &amp; Elisabeth Brookes atf Dahlbrook Family Trust 1,550,000 Ordinary Shares and 285,714 Options exercisable at \$0.07 ea expiring 11 December 2025</p>
<b>Class</b>	Ordinary Shares & Options
<b>Number acquired</b>	<p>Shares Indirect:  Tarandi 1996 Pty Ltd atf Dr DL Brookes Personal Superfund 750,000 Ordinary Shares = \$30,000  David &amp; Elisabeth Brookes atf Dahlbrook Family Trust 750,000 Ordinary Shares = \$30,000</p> <p>Unlisted Options:  Direct – David Brookes 1,500,000 Options  Indirect – David &amp; Elisabeth Brookes atf Dahlbrook Family Trust 1,000,000 Options</p>
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Shares: \$60,000 Options: Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<p>Direct:</p> <p>Ordinary Shares: 1,240,000 Ordinary Shares</p> <p>Options:</p> <p>900,000 at \$0.225 ea; vesting 450,000 16 November 2022</p> <p>450,000 16 November 2023 expire 14 November 2025</p> <p>175,000 Options exercisable at \$0.07 ea expiring 11 December 2025</p> <p>1,500,000 Options exercisable at \$0.10 ea expiring 9 July 2028</p> <p>Indirect – Tarandi 1996 Pty Ltd atf Dr DL Brookes Personal Superfund 2,490,002 Ordinary Shares; 396,429 Options exercisable at \$0.07 ea expiring 11 December 2025</p> <p>David &amp; Elisabeth Brookes atf Dahlbrook Family Trust 2,300,000 Ordinary Shares and 285,714 Options exercisable at \$0.07 ea expiring 11 December 2025; and 1,000,000 Options exercisable at \$0.10 ea expiring 9 July 2028</p>
<p><b>Nature of change</b></p> <p>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issued following Shareholder approval at the General Meeting held on 5 July 2024:</p> <p>Ordinary Shares at \$0.04 each purchased under the T2 Placement</p> <p>Unlisted Options issued exercisable at \$0.10 each; 50% vesting 12 months follow issue date &amp; 50% vesting 24 months follow issue date; expiring 9 July 2028</p>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<p><b>No. and class of securities to which interest related prior to change</b></p> <p>Note: Details are only required for a contract in relation to which the interest has changed</p>	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Anatara Lifesciences Limited</b>
<b>ABN</b>	<b>41 145 239 872</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	John Michailidis
<b>Date of last notice</b>	12 December 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	John Michailidis & Helen Michailidis atf Michailidis Family Account
<b>Date of change</b>	Ordinary Shares: 9 July 2024 Options: 9 July 2024
<b>No. of securities held prior to change</b>	Indirect: John Michailidis & Helen Michailidis atf Michailidis Family Account: 949,999 Ordinary Shares & 250,000 Unlisted Options exercisable at \$0.07 ea expiring 11 December 2025
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	Indirect: 250,000 Ordinary Shares at \$0.04 each purchased under the T2 Placement 1,000,000 Options issued exercisable at \$0.10 each; 50% vesting 12 months follow issue date & 50% vesting 24 months follow issue date; expiring 9 July 2028
<b>Number disposed</b>	Nil

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Shares: \$10,000 Options: Nil
<b>No. of securities held after change</b>	Indirect: John Michailidis & Helen Michailidis atf Michailidis Family Account: 1,199,999 Ordinary Shares & 250,000 Unlisted Options exercisable at \$0.07 ea expiring 11 December 2025 1,000,000 Unlisted Options exercisable at \$0.10 ea expiring 9 July 2028
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued following Shareholder approval at the General Meeting held on 5 July 2024: Ordinary Shares at \$0.04 each purchased under the T2 Placement Options issued exercisable at \$0.10 each; 50% vesting 12 months follow issue date & 50% vesting 24 months follow issue date; expiring 9 July 2028

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

## Part 3 – +Closed period

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Anatara Lifesciences Limited</b>
<b>ABN</b>	<b>41 145 239 872</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Nicholas William Haslam
<b>Date of last notice</b>	7 December 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	
<b>Date of change</b>	Options: 9 July 2024
<b>No. of securities held prior to change</b>	Direct: Nil
<b>Class</b>	Options
<b>Number acquired</b>	Direct: 1,000,000 Unlisted Options issued exercisable at \$0.10 each; 50% vesting 12 months follow issue date & 50% vesting 24 months follow issue date; expiring 9 July 2028
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.



## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	Direct: 1,000,000 Unlisted Options issued exercisable at \$0.10 each; 50% vesting 12 months follow issue date & 50% vesting 24 months follow issue date; expiring 9 July 2028
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issued following Shareholder approval at the General Meeting held on 5 July 2024: Unlisted Options issued exercisable at \$0.10 each; 50% vesting 12 months follow issue date & 50% vesting 24 months follow issue date; expiring 9 July 2028

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>If prior written clearance was provided, on what date was this provided?</b>	N/A
---	-----

---

+ See chapter 19 for defined terms.

For personal use only